How do you measure a year? Time? Worldly events? Personal growth? There are many things that you could measure the time of the year against. Here at Psychedelic Invest, we choose to measure the year in psychedelics!

The story of 2022 in psychedelics weaves through political offices, sterile research labs, colorful retreats, and more. It paints a picture of a future where all people have access to psychedelic treatments. 

This year has been a rollercoaster– to say the least. It has been a mix of ups, downs, and some extreme emotions. There has been fear, anger, excitement, and most importantly hope! Hope that millions of people will gain access to life-changing medicines.

Progress is never a straight shot. Progress hits hurdles, takes detours, and is often forced to forge new paths. That is what psychedelics have been doing for the past few decades– clawing their way back into the mainstream. This year all that hard work has come to an apex. Though the psychedelic industry continues to face challenges, the momentum and excitement are too great to stop at this point. 

The economic downturn has posed a hurdle for companies, but that hasn’t hindered the psychedelic industry from making huge strides in 2022. Capital has been more difficult to come by, which has caused companies to cut excess spending, and some companies to shut their doors. The companies that have strategically positioned themselves will continue to forge forward. 

In 2022, more people have had access to psychedelic treatment than ever before. The end of the psychedelic PR crisis has prompted more people to seek out these medicines than ever before. Perceptions have shifted and are allowing for changes on all levels of society. This year has been one of major progress for the industry, despite some hurdles, and it gives hope for the future of the psychedelic industry.

Next week, we’ll be publishing our batch of end-of-year reports. Until then, below is a summary of highlights from everything that has happened this year:

  • A survey found that ‘nearly two-thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psychedelic medicine (i.e. ketamine, psilocybin, and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD.’
  • Psychedelics Advancing Clinical Treatments (PACT) Caucus was created to increase awareness of psychedelic medicines in Congress.
  • MAPS has a successful phase 3 trial of MDMA for PTSD.
  • Wonderland Miami was the largest business gathering in the history of psychedelic medicine, with over 500 people gathering to discuss all things psychedelic!
  • Colorado votes to legalize psilocybin in November 2022 election.
  • Oregon finalizes regulations and plans to start taking applications for psilocybin clinic in January 2023.
  • First government-funded Ketamine clinical trial
  • Ketamine Clinics continue to open around the world, offering new solutions for depression, anxiety, and PTSD.

Psychedelic Invest PRO Reports

Stay tuned next week for the release of 2022: The Year in Psychedelics and all of its associated reports.

For those that are curious, we’ve shared the table of contents for the annual report below:

  1. Introduction
    1. 2022 Highlights!
  2. Psychedelic Investment Growth
    1. Public Trading
    2. Investment Funds and Venture Capital
    3. Macro Economic Factors
  3. Psychedelic Industry Growth
    1. Public Companies
    2. Private Companies
    3. Acquisitions & mergers
    4. Research and Development
      1. Patents
    5. Media
    6. Non-Profits
    7. Collaborations
    8. Clinics
    9. Retreats
    10. Job Growth
    11. Education
  4. Research in 2022
    1. Clinical Trials
      1. Top Trials
        1. Ketamine
        2. MAPS
        3. Compass Pathways
      2. PTSD
      3. Depression
      4. Anxiety
      5. Addiction
      6. Others
    2. Research Institutions
  5. Regulations and Politics
  6. Technology in Psychedelics
  7. Events and Conferences
  8. The Future of Psychedelics
    1. What to Expect in 2023
    2. Long-term Outcomes